BR112018069944A2 - construto de rna e métodos de uso do mesmo para melhorar os efeitos terapêuticos de células citotóxicas e células-tronco - Google Patents

construto de rna e métodos de uso do mesmo para melhorar os efeitos terapêuticos de células citotóxicas e células-tronco

Info

Publication number
BR112018069944A2
BR112018069944A2 BR112018069944A BR112018069944A BR112018069944A2 BR 112018069944 A2 BR112018069944 A2 BR 112018069944A2 BR 112018069944 A BR112018069944 A BR 112018069944A BR 112018069944 A BR112018069944 A BR 112018069944A BR 112018069944 A2 BR112018069944 A2 BR 112018069944A2
Authority
BR
Brazil
Prior art keywords
cells
methods
stem cells
therapeutic effects
rna construct
Prior art date
Application number
BR112018069944A
Other languages
English (en)
Inventor
Alici Evren
Original Assignee
Vycellix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vycellix Inc filed Critical Vycellix Inc
Publication of BR112018069944A2 publication Critical patent/BR112018069944A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Dispersion Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

a presente invenção refere-se a agonistas de rig i para melhorar os efeitos de células citotóxicas e célula-tronco. os agonistas de rig i podem ser utilizados in vivo como agentes terapêuticos de moléculas pequenas ou in vitro para melhorar as células para transferência de células adotivas. as aplicações incluem terapia de câncer, melhora do sistema imune, infecção viral crônica e tratamento de inflamação induzida por vírus e melhora de terapias baseadas em vírus.
BR112018069944A 2016-04-01 2017-04-01 construto de rna e métodos de uso do mesmo para melhorar os efeitos terapêuticos de células citotóxicas e células-tronco BR112018069944A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662316679P 2016-04-01 2016-04-01
PCT/US2017/025656 WO2017173427A1 (en) 2016-04-01 2017-04-01 Novel rna construct and methods of use thereof for enhancing the therapeutic effects of cytotoxic cells and stem cells

Publications (1)

Publication Number Publication Date
BR112018069944A2 true BR112018069944A2 (pt) 2019-02-05

Family

ID=59965294

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018069944A BR112018069944A2 (pt) 2016-04-01 2017-04-01 construto de rna e métodos de uso do mesmo para melhorar os efeitos terapêuticos de células citotóxicas e células-tronco

Country Status (10)

Country Link
US (1) US20190076463A1 (pt)
EP (1) EP3436031A4 (pt)
JP (1) JP7155011B2 (pt)
KR (3) KR20180128039A (pt)
CN (1) CN108883124B (pt)
AU (2) AU2017240250A1 (pt)
BR (1) BR112018069944A2 (pt)
CA (1) CA3019577A1 (pt)
IL (1) IL261996A (pt)
WO (1) WO2017173427A1 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9790509B2 (en) 2014-07-18 2017-10-17 Oregon Health & Science University 5′-triphosphate oligoribonucleotides
US11382966B2 (en) 2017-03-24 2022-07-12 Rigontec Gmbh Method for designing RIG-I ligands
EP3610022A1 (en) 2017-04-14 2020-02-19 Tollnine, Inc. Immunomodulating polynucleotides, antibody conjugates thereof, and methods of their use
US20200368268A1 (en) * 2018-01-08 2020-11-26 Novartis Ag Immune-enhancing rnas for combination with chimeric antigen receptor therapy
US10907161B2 (en) 2018-04-19 2021-02-02 Checkmate Pharmaceuticals, Inc. Synthetic RIG-I-like receptor agonists
WO2019204179A1 (en) * 2018-04-20 2019-10-24 Merck Sharp & Dohme Corp. Novel substituted rig-i agonists: compositions and methods thereof
WO2020089811A1 (en) * 2018-10-31 2020-05-07 Novartis Ag Dc-sign antibody drug conjugates
WO2020225779A1 (en) * 2019-05-09 2020-11-12 Istituto Pasteur Italia - Fondazione Cenci Bolognetti Rig-i agonists for cancer treatment and immunotherapy
AU2020389422A1 (en) * 2019-11-20 2022-06-02 Gi Cell, Inc. Medium composition for culturing T cells and method for culturing T cells using same
EP3914699A4 (en) * 2019-12-09 2023-03-29 ImmunityBio, Inc. SCREENING OF CELLULAR CLONES EXPRESSING POLYGENIC TRANSGENES BY POSITIVE SELECTION NOT DEPENDENT ON ANTIBIOTICS
US11920136B2 (en) 2020-02-28 2024-03-05 Tallac Therapeutics, Inc. Transglutaminase-mediated conjugation
KR20240043747A (ko) 2021-07-02 2024-04-03 예일 유니버시티 암을 치료하기 위한 조성물 및 방법
AU2022340804A1 (en) 2021-08-31 2024-03-21 Gennao Bio, Inc. Compositions and methods for treating cancers
WO2023168352A1 (en) 2022-03-03 2023-09-07 Yale University Humanized 3e10 antibodies, variants, and antigen binding fragments thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5689413B2 (ja) * 2008-05-21 2015-03-25 ライニッシュ フリードリッヒ−ウィルヘルムズ−ユニバーシタット ボン 平滑末端を有する５’三リン酸オリゴヌクレオチドおよびその使用
EP2833918B1 (en) * 2012-04-05 2019-05-08 Massachusetts Institute of Technology Immunostimulatory compositions and methods of use thereof
US10849963B2 (en) * 2014-03-17 2020-12-01 Bundesrepublik Deutschland letztvertreten durch das Robl Koch-Institut vertreten durch seinen Präsidenten Medicament for use in a method of inducing or extending a cellular cytotoxic immune response
US10273484B2 (en) * 2014-03-24 2019-04-30 Riboxx Gmbh Double-stranded RNA conjugates and their use
US9790509B2 (en) * 2014-07-18 2017-10-17 Oregon Health & Science University 5′-triphosphate oligoribonucleotides

Also Published As

Publication number Publication date
KR20220143151A (ko) 2022-10-24
EP3436031A4 (en) 2019-09-18
CN108883124B (zh) 2022-05-10
IL261996A (en) 2018-10-31
KR20180128039A (ko) 2018-11-30
EP3436031A1 (en) 2019-02-06
CN108883124A (zh) 2018-11-23
WO2017173427A1 (en) 2017-10-05
KR20240044410A (ko) 2024-04-04
JP2019510035A (ja) 2019-04-11
JP7155011B2 (ja) 2022-10-18
AU2017240250A1 (en) 2018-10-11
US20190076463A1 (en) 2019-03-14
AU2024202032A1 (en) 2024-05-02
CA3019577A1 (en) 2017-10-05

Similar Documents

Publication Publication Date Title
BR112018069944A2 (pt) construto de rna e métodos de uso do mesmo para melhorar os efeitos terapêuticos de células citotóxicas e células-tronco
EA201590343A1 (ru) Алкилпиримидиновые производные для лечения вирусных инфекций и дальнейших заболеваний
EA201690093A1 (ru) Производные пирроло[3,2-d]пиримидина для лечения вирусных инфекций и других заболеваний
EA201890006A1 (ru) Применение экзосом для лечения болезни
EA201401281A1 (ru) D-аминокислотные химические соединения для лечения заболеваний печени
EA202090662A2 (ru) ПРОИЗВОДНЫЕ ПИРРОЛО[3,2-d]ПИРИМИДИНА ДЛЯ ЛЕЧЕНИЯ ВИРУСНЫХ ИНФЕКЦИЙ И ДРУГИХ ЗАБОЛЕВАНИЙ
BR112016004095A2 (pt) administração de enzimas de empobrecimento de quinurenina para a terapia contra tumores
MX2017004039A (es) Fosforamiditas de n-acetilgalactosamina (galnac), conjugados de acido nucleico de las mismas y su uso.
EA201700181A1 (ru) Композиции аденозиндеаминазы-2 (ада-2), их варианты и способы использования
EA201590667A1 (ru) Ациламинопиримидиновые производные для лечения вирусных инфекций и других заболеваний
EA201991767A1 (ru) Производные пурина для лечения вирусных инфекций
EA201391719A1 (ru) Хиназолиновые производные для лечения вирусных инфекций и дальнейших заболеваний
BR112015018104A2 (pt) polipeptídeos de gdf15 modificados, seu uso, composições compreendendo os mesmos e recipiente estéril compreendendo as referidas composições
BR112014018728A8 (pt) Compostos de purinonas como inibidores de quinase
CO2019005466A2 (es) Crenolanib para tratar mutaciones asociadas con trastornos proliferativos con flt3 mutado
EA201591924A1 (ru) Способы лечения злокачественной опухоли с использованием комбинированной терапии с коферментом q10
CL2016002088A1 (es) Anticuerpos monoclonales biespecificos contra il-13/il-17; ácido nucleico; célula huésped; método de producción del anticuerpo; inmunoconjugados; formulación farmacéutica; y usos de los anticuerpos biespecíficios para el tratamiento del asma moderada a severa y/o asma eosinofílica.
BR112017009552A8 (pt) Métodos para alvejar o controle transcricional em regiões de super-realçador
EA201491702A1 (ru) Оптимизированные терапевтические агенты для подкожного введения
EA201691385A1 (ru) Комбинированная терапия рака
BR112018015893A2 (pt) vacinas de câncer e métodos de tratamento usando as mesmas
BR112016010336A2 (pt) Anticorpo anti-humano-her3 alostérico não competitivo com neuregulina, fragmento de anticorpo, sequência de ácido nucleico, vetor, célula hospedeira, composição farmacêutica e método para tratamento de câncer
EP3377622A4 (en) TARGETED DISTRIBUTION OF BIOVERCAPED THERAPEUTIC PROTEINS IN CROP CELLS TO CERTAIN CELL TYPES FOR THE TREATMENT OF DISEASES
TR201908872T4 (tr) Üçlü negatif meme kanserini tedavi etmek için ajanlar.
EA201592242A1 (ru) Производные пиридона для лечения вирусных инфекций и других заболеваний

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI N? 10196/2001, QUE MODIFICOU A LEI N? 9279/96, A CONCESS?O DA PATENTE EST? CONDICIONADA ? ANU?NCIA PR?VIA DA ANVISA. CONSIDERANDO A APROVA??O DOS TERMOS DO PARECER N? 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL N? 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVID?NCIAS CAB?VEIS.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2631 DE 08/06/2021 POR TER SIDO INDEVIDA.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]